Review





Similar Products

96
Proteintech tom20
Validation of E-cadherin manipulation and characterization of ROS sources and mitochondrial proteins. (A) Western blot of lysates derived from MMTV-PyMT;Cdh1 fl/fl organoids treated with Ad-Cre or Ad-GFP. Lysates were immunoblotted for E-cadherin (ECCD-2 clone) and β-actin. (B) Expression of FLAG-tagged E-cadherin rescue constructs. Representative western blot of organoid-derived cells expressing the indicated FLAG-tagged E-cadherin constructs following infection with XPIR (empty vector), full-length E-cadherin, ΔEct, W2A, ΔCyto, D758A–761AA, or ΔLast80 constructs. Lysates were probed with anti-FLAG antibody to assess the relative expression of rescue constructs. (C) Summary of small molecules used in ROS inhibitor screen. (D) Dose–response for organoids treated with each ROS inhibitor, with and without intact E-cadherin. For each ROS inhibitor, n = 31 vehicle wells were analyzed, n = 12 for 1, 5, 10, 20, and 40 µM conditions. r = 2 biological replicates. Error bars represent the standard deviation. (E) Quantification of the colony formation assay for SB525334 (TGFBi) and NAC, positive controls confirmed to rescue in previous studies. For Ad-Cre-null–treated clusters, vehicle n = 16 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. For Ad-Cre–treated clusters, vehicle n = 15 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. r = 3 biological replicates. Interaction, *P < 0.05; **P <0 .01; ***P < 0.0001; Treatment (Ad-Cre vs Ad-Cre-null), ***P < 0.0001 by 2-way ANOVA with multiple comparisons. Error bars represent the standard deviation. (F) Scanning confocal micrograph of CellROX intensity in E-cadherin intact (top) and deleted (bottom) at high magnification (60×). (G and G′) Western blot analysis of mitochondrial fission, fusion, and mitochondrial mass–associated proteins in control and E-cadherin knockout cells. Lysates from control and E-cadherin knockout conditions were probed for E-cadherin to confirm efficient deletion, as well as Drp1, phospho-Drp1 (S616, S637), Opa1, Mfn1, Mfn2, Mid51/Mief1, Mid49, Mff, Fis1, <t>Tom20,</t> and HSP60. Relative protein abundance is quantified in the right panel. Protein intensities were normalized to α-tubulin and plotted relative to control cells. Two biological replicates were analyzed, each with technical triplicates. Statistical significance was determined by Welch’s t test; ns, not significant; *P < 0.05; ***P < 0.001; ****P < 0.0001. Error bars represent the standard deviation. Source data are available for this figure: .
Tom20, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tom20/TOM20+Antibody/pmc13689684-155-92-94
Average 96 stars, based on 1 article reviews
tom20 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech antibodies against tomm20
Validation of E-cadherin manipulation and characterization of ROS sources and mitochondrial proteins. (A) Western blot of lysates derived from MMTV-PyMT;Cdh1 fl/fl organoids treated with Ad-Cre or Ad-GFP. Lysates were immunoblotted for E-cadherin (ECCD-2 clone) and β-actin. (B) Expression of FLAG-tagged E-cadherin rescue constructs. Representative western blot of organoid-derived cells expressing the indicated FLAG-tagged E-cadherin constructs following infection with XPIR (empty vector), full-length E-cadherin, ΔEct, W2A, ΔCyto, D758A–761AA, or ΔLast80 constructs. Lysates were probed with anti-FLAG antibody to assess the relative expression of rescue constructs. (C) Summary of small molecules used in ROS inhibitor screen. (D) Dose–response for organoids treated with each ROS inhibitor, with and without intact E-cadherin. For each ROS inhibitor, n = 31 vehicle wells were analyzed, n = 12 for 1, 5, 10, 20, and 40 µM conditions. r = 2 biological replicates. Error bars represent the standard deviation. (E) Quantification of the colony formation assay for SB525334 (TGFBi) and NAC, positive controls confirmed to rescue in previous studies. For Ad-Cre-null–treated clusters, vehicle n = 16 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. For Ad-Cre–treated clusters, vehicle n = 15 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. r = 3 biological replicates. Interaction, *P < 0.05; **P <0 .01; ***P < 0.0001; Treatment (Ad-Cre vs Ad-Cre-null), ***P < 0.0001 by 2-way ANOVA with multiple comparisons. Error bars represent the standard deviation. (F) Scanning confocal micrograph of CellROX intensity in E-cadherin intact (top) and deleted (bottom) at high magnification (60×). (G and G′) Western blot analysis of mitochondrial fission, fusion, and mitochondrial mass–associated proteins in control and E-cadherin knockout cells. Lysates from control and E-cadherin knockout conditions were probed for E-cadherin to confirm efficient deletion, as well as Drp1, phospho-Drp1 (S616, S637), Opa1, Mfn1, Mfn2, Mid51/Mief1, Mid49, Mff, Fis1, <t>Tom20,</t> and HSP60. Relative protein abundance is quantified in the right panel. Protein intensities were normalized to α-tubulin and plotted relative to control cells. Two biological replicates were analyzed, each with technical triplicates. Statistical significance was determined by Welch’s t test; ns, not significant; *P < 0.05; ***P < 0.001; ****P < 0.0001. Error bars represent the standard deviation. Source data are available for this figure: .
Antibodies Against Tomm20, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tom20/TOM20+Antibody/10__4103_slash_nrr__nrronline___d___26___00892-175-0-19
Average 96 stars, based on 1 article reviews
antibodies against tomm20 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech rabbit anti tomm20
Validation of E-cadherin manipulation and characterization of ROS sources and mitochondrial proteins. (A) Western blot of lysates derived from MMTV-PyMT;Cdh1 fl/fl organoids treated with Ad-Cre or Ad-GFP. Lysates were immunoblotted for E-cadherin (ECCD-2 clone) and β-actin. (B) Expression of FLAG-tagged E-cadherin rescue constructs. Representative western blot of organoid-derived cells expressing the indicated FLAG-tagged E-cadherin constructs following infection with XPIR (empty vector), full-length E-cadherin, ΔEct, W2A, ΔCyto, D758A–761AA, or ΔLast80 constructs. Lysates were probed with anti-FLAG antibody to assess the relative expression of rescue constructs. (C) Summary of small molecules used in ROS inhibitor screen. (D) Dose–response for organoids treated with each ROS inhibitor, with and without intact E-cadherin. For each ROS inhibitor, n = 31 vehicle wells were analyzed, n = 12 for 1, 5, 10, 20, and 40 µM conditions. r = 2 biological replicates. Error bars represent the standard deviation. (E) Quantification of the colony formation assay for SB525334 (TGFBi) and NAC, positive controls confirmed to rescue in previous studies. For Ad-Cre-null–treated clusters, vehicle n = 16 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. For Ad-Cre–treated clusters, vehicle n = 15 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. r = 3 biological replicates. Interaction, *P < 0.05; **P <0 .01; ***P < 0.0001; Treatment (Ad-Cre vs Ad-Cre-null), ***P < 0.0001 by 2-way ANOVA with multiple comparisons. Error bars represent the standard deviation. (F) Scanning confocal micrograph of CellROX intensity in E-cadherin intact (top) and deleted (bottom) at high magnification (60×). (G and G′) Western blot analysis of mitochondrial fission, fusion, and mitochondrial mass–associated proteins in control and E-cadherin knockout cells. Lysates from control and E-cadherin knockout conditions were probed for E-cadherin to confirm efficient deletion, as well as Drp1, phospho-Drp1 (S616, S637), Opa1, Mfn1, Mfn2, Mid51/Mief1, Mid49, Mff, Fis1, <t>Tom20,</t> and HSP60. Relative protein abundance is quantified in the right panel. Protein intensities were normalized to α-tubulin and plotted relative to control cells. Two biological replicates were analyzed, each with technical triplicates. Statistical significance was determined by Welch’s t test; ns, not significant; *P < 0.05; ***P < 0.001; ****P < 0.0001. Error bars represent the standard deviation. Source data are available for this figure: .
Rabbit Anti Tomm20, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tom20/TOM20+Antibody/10__1038_slash_s41467___026___78907___w-480-105-107
Average 96 stars, based on 1 article reviews
rabbit anti tomm20 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

97
Cell Signaling Technology Inc antibody against tom20
Validation of E-cadherin manipulation and characterization of ROS sources and mitochondrial proteins. (A) Western blot of lysates derived from MMTV-PyMT;Cdh1 fl/fl organoids treated with Ad-Cre or Ad-GFP. Lysates were immunoblotted for E-cadherin (ECCD-2 clone) and β-actin. (B) Expression of FLAG-tagged E-cadherin rescue constructs. Representative western blot of organoid-derived cells expressing the indicated FLAG-tagged E-cadherin constructs following infection with XPIR (empty vector), full-length E-cadherin, ΔEct, W2A, ΔCyto, D758A–761AA, or ΔLast80 constructs. Lysates were probed with anti-FLAG antibody to assess the relative expression of rescue constructs. (C) Summary of small molecules used in ROS inhibitor screen. (D) Dose–response for organoids treated with each ROS inhibitor, with and without intact E-cadherin. For each ROS inhibitor, n = 31 vehicle wells were analyzed, n = 12 for 1, 5, 10, 20, and 40 µM conditions. r = 2 biological replicates. Error bars represent the standard deviation. (E) Quantification of the colony formation assay for SB525334 (TGFBi) and NAC, positive controls confirmed to rescue in previous studies. For Ad-Cre-null–treated clusters, vehicle n = 16 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. For Ad-Cre–treated clusters, vehicle n = 15 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. r = 3 biological replicates. Interaction, *P < 0.05; **P <0 .01; ***P < 0.0001; Treatment (Ad-Cre vs Ad-Cre-null), ***P < 0.0001 by 2-way ANOVA with multiple comparisons. Error bars represent the standard deviation. (F) Scanning confocal micrograph of CellROX intensity in E-cadherin intact (top) and deleted (bottom) at high magnification (60×). (G and G′) Western blot analysis of mitochondrial fission, fusion, and mitochondrial mass–associated proteins in control and E-cadherin knockout cells. Lysates from control and E-cadherin knockout conditions were probed for E-cadherin to confirm efficient deletion, as well as Drp1, phospho-Drp1 (S616, S637), Opa1, Mfn1, Mfn2, Mid51/Mief1, Mid49, Mff, Fis1, <t>Tom20,</t> and HSP60. Relative protein abundance is quantified in the right panel. Protein intensities were normalized to α-tubulin and plotted relative to control cells. Two biological replicates were analyzed, each with technical triplicates. Statistical significance was determined by Welch’s t test; ns, not significant; *P < 0.05; ***P < 0.001; ****P < 0.0001. Error bars represent the standard deviation. Source data are available for this figure: .
Antibody Against Tom20, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tom20/Tom20+Rabbit+mAb/pm42883149-282-12-18
Average 97 stars, based on 1 article reviews
antibody against tom20 - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology mitochondrial membrane protein tom20
Validation of E-cadherin manipulation and characterization of ROS sources and mitochondrial proteins. (A) Western blot of lysates derived from MMTV-PyMT;Cdh1 fl/fl organoids treated with Ad-Cre or Ad-GFP. Lysates were immunoblotted for E-cadherin (ECCD-2 clone) and β-actin. (B) Expression of FLAG-tagged E-cadherin rescue constructs. Representative western blot of organoid-derived cells expressing the indicated FLAG-tagged E-cadherin constructs following infection with XPIR (empty vector), full-length E-cadherin, ΔEct, W2A, ΔCyto, D758A–761AA, or ΔLast80 constructs. Lysates were probed with anti-FLAG antibody to assess the relative expression of rescue constructs. (C) Summary of small molecules used in ROS inhibitor screen. (D) Dose–response for organoids treated with each ROS inhibitor, with and without intact E-cadherin. For each ROS inhibitor, n = 31 vehicle wells were analyzed, n = 12 for 1, 5, 10, 20, and 40 µM conditions. r = 2 biological replicates. Error bars represent the standard deviation. (E) Quantification of the colony formation assay for SB525334 (TGFBi) and NAC, positive controls confirmed to rescue in previous studies. For Ad-Cre-null–treated clusters, vehicle n = 16 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. For Ad-Cre–treated clusters, vehicle n = 15 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. r = 3 biological replicates. Interaction, *P < 0.05; **P <0 .01; ***P < 0.0001; Treatment (Ad-Cre vs Ad-Cre-null), ***P < 0.0001 by 2-way ANOVA with multiple comparisons. Error bars represent the standard deviation. (F) Scanning confocal micrograph of CellROX intensity in E-cadherin intact (top) and deleted (bottom) at high magnification (60×). (G and G′) Western blot analysis of mitochondrial fission, fusion, and mitochondrial mass–associated proteins in control and E-cadherin knockout cells. Lysates from control and E-cadherin knockout conditions were probed for E-cadherin to confirm efficient deletion, as well as Drp1, phospho-Drp1 (S616, S637), Opa1, Mfn1, Mfn2, Mid51/Mief1, Mid49, Mff, Fis1, <t>Tom20,</t> and HSP60. Relative protein abundance is quantified in the right panel. Protein intensities were normalized to α-tubulin and plotted relative to control cells. Two biological replicates were analyzed, each with technical triplicates. Statistical significance was determined by Welch’s t test; ns, not significant; *P < 0.05; ***P < 0.001; ****P < 0.0001. Error bars represent the standard deviation. Source data are available for this figure: .
Mitochondrial Membrane Protein Tom20, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tom20/Tom20+Antibody/pm42878775-77-21-25
Average 96 stars, based on 1 article reviews
mitochondrial membrane protein tom20 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
ABclonal Biotechnology anti tom20
Validation of E-cadherin manipulation and characterization of ROS sources and mitochondrial proteins. (A) Western blot of lysates derived from MMTV-PyMT;Cdh1 fl/fl organoids treated with Ad-Cre or Ad-GFP. Lysates were immunoblotted for E-cadherin (ECCD-2 clone) and β-actin. (B) Expression of FLAG-tagged E-cadherin rescue constructs. Representative western blot of organoid-derived cells expressing the indicated FLAG-tagged E-cadherin constructs following infection with XPIR (empty vector), full-length E-cadherin, ΔEct, W2A, ΔCyto, D758A–761AA, or ΔLast80 constructs. Lysates were probed with anti-FLAG antibody to assess the relative expression of rescue constructs. (C) Summary of small molecules used in ROS inhibitor screen. (D) Dose–response for organoids treated with each ROS inhibitor, with and without intact E-cadherin. For each ROS inhibitor, n = 31 vehicle wells were analyzed, n = 12 for 1, 5, 10, 20, and 40 µM conditions. r = 2 biological replicates. Error bars represent the standard deviation. (E) Quantification of the colony formation assay for SB525334 (TGFBi) and NAC, positive controls confirmed to rescue in previous studies. For Ad-Cre-null–treated clusters, vehicle n = 16 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. For Ad-Cre–treated clusters, vehicle n = 15 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. r = 3 biological replicates. Interaction, *P < 0.05; **P <0 .01; ***P < 0.0001; Treatment (Ad-Cre vs Ad-Cre-null), ***P < 0.0001 by 2-way ANOVA with multiple comparisons. Error bars represent the standard deviation. (F) Scanning confocal micrograph of CellROX intensity in E-cadherin intact (top) and deleted (bottom) at high magnification (60×). (G and G′) Western blot analysis of mitochondrial fission, fusion, and mitochondrial mass–associated proteins in control and E-cadherin knockout cells. Lysates from control and E-cadherin knockout conditions were probed for E-cadherin to confirm efficient deletion, as well as Drp1, phospho-Drp1 (S616, S637), Opa1, Mfn1, Mfn2, Mid51/Mief1, Mid49, Mff, Fis1, <t>Tom20,</t> and HSP60. Relative protein abundance is quantified in the right panel. Protein intensities were normalized to α-tubulin and plotted relative to control cells. Two biological replicates were analyzed, each with technical triplicates. Statistical significance was determined by Welch’s t test; ns, not significant; *P < 0.05; ***P < 0.001; ****P < 0.0001. Error bars represent the standard deviation. Source data are available for this figure: .
Anti Tom20, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tom20/TOM20+Rabbit+mAb/pm42880285-1624-95-96
Average 96 stars, based on 1 article reviews
anti tom20 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech anti tom20 antibody
Validation of E-cadherin manipulation and characterization of ROS sources and mitochondrial proteins. (A) Western blot of lysates derived from MMTV-PyMT;Cdh1 fl/fl organoids treated with Ad-Cre or Ad-GFP. Lysates were immunoblotted for E-cadherin (ECCD-2 clone) and β-actin. (B) Expression of FLAG-tagged E-cadherin rescue constructs. Representative western blot of organoid-derived cells expressing the indicated FLAG-tagged E-cadherin constructs following infection with XPIR (empty vector), full-length E-cadherin, ΔEct, W2A, ΔCyto, D758A–761AA, or ΔLast80 constructs. Lysates were probed with anti-FLAG antibody to assess the relative expression of rescue constructs. (C) Summary of small molecules used in ROS inhibitor screen. (D) Dose–response for organoids treated with each ROS inhibitor, with and without intact E-cadherin. For each ROS inhibitor, n = 31 vehicle wells were analyzed, n = 12 for 1, 5, 10, 20, and 40 µM conditions. r = 2 biological replicates. Error bars represent the standard deviation. (E) Quantification of the colony formation assay for SB525334 (TGFBi) and NAC, positive controls confirmed to rescue in previous studies. For Ad-Cre-null–treated clusters, vehicle n = 16 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. For Ad-Cre–treated clusters, vehicle n = 15 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. r = 3 biological replicates. Interaction, *P < 0.05; **P <0 .01; ***P < 0.0001; Treatment (Ad-Cre vs Ad-Cre-null), ***P < 0.0001 by 2-way ANOVA with multiple comparisons. Error bars represent the standard deviation. (F) Scanning confocal micrograph of CellROX intensity in E-cadherin intact (top) and deleted (bottom) at high magnification (60×). (G and G′) Western blot analysis of mitochondrial fission, fusion, and mitochondrial mass–associated proteins in control and E-cadherin knockout cells. Lysates from control and E-cadherin knockout conditions were probed for E-cadherin to confirm efficient deletion, as well as Drp1, phospho-Drp1 (S616, S637), Opa1, Mfn1, Mfn2, Mid51/Mief1, Mid49, Mff, Fis1, <t>Tom20,</t> and HSP60. Relative protein abundance is quantified in the right panel. Protein intensities were normalized to α-tubulin and plotted relative to control cells. Two biological replicates were analyzed, each with technical triplicates. Statistical significance was determined by Welch’s t test; ns, not significant; *P < 0.05; ***P < 0.001; ****P < 0.0001. Error bars represent the standard deviation. Source data are available for this figure: .
Anti Tom20 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tom20/TOM20+Antibody/pm42875724-494-18-33
Average 96 stars, based on 1 article reviews
anti tom20 antibody - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


Validation of E-cadherin manipulation and characterization of ROS sources and mitochondrial proteins. (A) Western blot of lysates derived from MMTV-PyMT;Cdh1 fl/fl organoids treated with Ad-Cre or Ad-GFP. Lysates were immunoblotted for E-cadherin (ECCD-2 clone) and β-actin. (B) Expression of FLAG-tagged E-cadherin rescue constructs. Representative western blot of organoid-derived cells expressing the indicated FLAG-tagged E-cadherin constructs following infection with XPIR (empty vector), full-length E-cadherin, ΔEct, W2A, ΔCyto, D758A–761AA, or ΔLast80 constructs. Lysates were probed with anti-FLAG antibody to assess the relative expression of rescue constructs. (C) Summary of small molecules used in ROS inhibitor screen. (D) Dose–response for organoids treated with each ROS inhibitor, with and without intact E-cadherin. For each ROS inhibitor, n = 31 vehicle wells were analyzed, n = 12 for 1, 5, 10, 20, and 40 µM conditions. r = 2 biological replicates. Error bars represent the standard deviation. (E) Quantification of the colony formation assay for SB525334 (TGFBi) and NAC, positive controls confirmed to rescue in previous studies. For Ad-Cre-null–treated clusters, vehicle n = 16 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. For Ad-Cre–treated clusters, vehicle n = 15 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. r = 3 biological replicates. Interaction, *P < 0.05; **P <0 .01; ***P < 0.0001; Treatment (Ad-Cre vs Ad-Cre-null), ***P < 0.0001 by 2-way ANOVA with multiple comparisons. Error bars represent the standard deviation. (F) Scanning confocal micrograph of CellROX intensity in E-cadherin intact (top) and deleted (bottom) at high magnification (60×). (G and G′) Western blot analysis of mitochondrial fission, fusion, and mitochondrial mass–associated proteins in control and E-cadherin knockout cells. Lysates from control and E-cadherin knockout conditions were probed for E-cadherin to confirm efficient deletion, as well as Drp1, phospho-Drp1 (S616, S637), Opa1, Mfn1, Mfn2, Mid51/Mief1, Mid49, Mff, Fis1, Tom20, and HSP60. Relative protein abundance is quantified in the right panel. Protein intensities were normalized to α-tubulin and plotted relative to control cells. Two biological replicates were analyzed, each with technical triplicates. Statistical significance was determined by Welch’s t test; ns, not significant; *P < 0.05; ***P < 0.001; ****P < 0.0001. Error bars represent the standard deviation. Source data are available for this figure: .

Journal: The Journal of Cell Biology

Article Title: Nonadhesive functions of E-cadherin promote cancer cell survival and metastasis

doi: 10.1083/jcb.202507222

Figure Lengend Snippet: Validation of E-cadherin manipulation and characterization of ROS sources and mitochondrial proteins. (A) Western blot of lysates derived from MMTV-PyMT;Cdh1 fl/fl organoids treated with Ad-Cre or Ad-GFP. Lysates were immunoblotted for E-cadherin (ECCD-2 clone) and β-actin. (B) Expression of FLAG-tagged E-cadherin rescue constructs. Representative western blot of organoid-derived cells expressing the indicated FLAG-tagged E-cadherin constructs following infection with XPIR (empty vector), full-length E-cadherin, ΔEct, W2A, ΔCyto, D758A–761AA, or ΔLast80 constructs. Lysates were probed with anti-FLAG antibody to assess the relative expression of rescue constructs. (C) Summary of small molecules used in ROS inhibitor screen. (D) Dose–response for organoids treated with each ROS inhibitor, with and without intact E-cadherin. For each ROS inhibitor, n = 31 vehicle wells were analyzed, n = 12 for 1, 5, 10, 20, and 40 µM conditions. r = 2 biological replicates. Error bars represent the standard deviation. (E) Quantification of the colony formation assay for SB525334 (TGFBi) and NAC, positive controls confirmed to rescue in previous studies. For Ad-Cre-null–treated clusters, vehicle n = 16 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. For Ad-Cre–treated clusters, vehicle n = 15 total wells were analyzed, TGFBi n = 6, NAC n = 6, combination treatment n = 6. r = 3 biological replicates. Interaction, *P < 0.05; **P <0 .01; ***P < 0.0001; Treatment (Ad-Cre vs Ad-Cre-null), ***P < 0.0001 by 2-way ANOVA with multiple comparisons. Error bars represent the standard deviation. (F) Scanning confocal micrograph of CellROX intensity in E-cadherin intact (top) and deleted (bottom) at high magnification (60×). (G and G′) Western blot analysis of mitochondrial fission, fusion, and mitochondrial mass–associated proteins in control and E-cadherin knockout cells. Lysates from control and E-cadherin knockout conditions were probed for E-cadherin to confirm efficient deletion, as well as Drp1, phospho-Drp1 (S616, S637), Opa1, Mfn1, Mfn2, Mid51/Mief1, Mid49, Mff, Fis1, Tom20, and HSP60. Relative protein abundance is quantified in the right panel. Protein intensities were normalized to α-tubulin and plotted relative to control cells. Two biological replicates were analyzed, each with technical triplicates. Statistical significance was determined by Welch’s t test; ns, not significant; *P < 0.05; ***P < 0.001; ****P < 0.0001. Error bars represent the standard deviation. Source data are available for this figure: .

Article Snippet: Primary antibodies used in the study included rat E-cadherin (ECCD-2 clone, M108; Takara), rabbit β-actin (A2103; Sigma-Aldrich), mouse FLAG (F1804; Sigma-Aldrich), rabbit αE-catenin (3236; Cell Signaling), rabbit β-catenin (8480; Cell Signaling), E-cadherin (14472; Cell Signaling Technology), Drp1 (611113; BD Transduction Laboratories), phospho-Drp1 S616 (3455; Cell Signaling Technology), phospho-Drp1 S637 (6319; Cell Signaling Technology), Opa1 (612607; BD Transduction Laboratories), Mfn1 (13798-1-AP; Proteintech), Mfn2 (ab57602; Abcam), Mid51/Mief1 (20164-1-AP; Proteintech), Mid49/Mief2 (16413-1-AP; Proteintech), Mff (gifted from Dr. Alexander M. van der Bliek, University of California Los Angeles, Los Angeles, CA, USA; ), Fis1 (10956-1-AP; Proteintech), Tom20 (11802-1-AP; Proteintech), α-tubulin (2125; Cell Signaling Technology), Hsp60 (12165; Cell Signaling Technology), Gapdh (MA5-15738; Thermo Fisher Scientific).

Techniques: Biomarker Discovery, Western Blot, Derivative Assay, Organoids, Expressing, Construct, Infection, Plasmid Preparation, Standard Deviation, Colony Assay, Confocal, Analysis, Control, Knock-Out, Quantitative Proteomics